Moderna’s melanoma vaccine breakthrough raises hopes—and demands proof

Moderna’s melanoma vaccine breakthrough raises hopes—and demands proof
A personalized mRNA treatment for melanoma has produced the kind of late-stage trial result cancer researchers have long chased. Yet the announcement’s most important numbers remain under wraps, leaving the promise of a new therapy to be tested against the full evidence.

Moderna and Merck said Wednesday that their individualized treatment, intismeran, improved recurrence-free survival and distant metastasis-free survival when combined with Merck’s Keytruda after surgery for high-risk melanoma. The Phase 3 study enrolled 1,137 patients with stage IIB–IV disease whose tumors had been removed, assigning them two-to-one to the combination or Keytruda alone for roughly a year.

The treatment is built around a patient’s own tumor: researchers sequence it, select up to 34 cancer-specific mutations, then use synthetic mRNA to train the immune system to recognize those targets. Moderna and Merck said the interim findings were statistically significant and clinically meaningful, but did not disclose the magnitude of the benefit; detailed results are due at a future medical conference.

The companies cast the result as a turning point. Trial leader Georgina Long called it “a landmark moment” that could establish “a new treatment paradigm,” while Merck Research Laboratories president Dean Li said it reinforced the case for personalized cancer treatment.

Outside enthusiasm came with a sharper caveat. Oxford cancer specialist Lennard Lee called it the first positive Phase 3 trial for both an individualized neoantigen therapy and an mRNA cancer treatment, but said researchers still need subgroup, quality-of-life and mature overall-survival data to establish who benefits most.

The news also revived a distinction often lost in arguments over vaccines. Yann LeCun amplified a post stressing that these newer cancer vaccines are therapeutic—designed to treat existing cancer, rather than prevent infection—and declaring that 2026 was when they “stopped being sci-fi.” Investors responded more immediately: Moderna shares doubled on the reported skin-cancer vaccine success.

Continue reading https://foxvector.com/stories/01a02b29-f155-1195-738d-177463943e9e